Key result
IGFBP-1 deletion reduces arterial endothelial regeneration by ~14 percentage points after wire injury.
Why the study?
Human studies suggest low IGFBP-1 levels are permissive for diabetes and cardiovascular disease, but whether loss of IGFBP-1 plays a causal role in predisposing to cardiometabolic disease remained unknown.
Does loss or gain of function of IGFBP-1 modulate metabolic homeostasis, endothelial repair, and ischemia-induced angiogenesis in lean, obese, and insulin-resistant mice?
Does loss or gain of function of IGFBP-1 modulate metabolic homeostasis, endothelial repair, and ischemia-induced angiogenesis in lean, obese, and insulin-resistant mice?
Although loss of IGFBP-1 does not cause metabolic dysfunction or glucose intolerance in mice, IGFBP-1 is required for endogenous endothelial repair after vascular injury and its overexpression promotes ischemic neovascularization in the setting of insulin resistance.
Answers are grounded in this paper and cite their sources.
IGFBP-1 may support endothelial repair in insulin-resistant models; hypothesis-generating for human vascular therapies.
We have previously reported that overexpression of human insulin-like growth factor binding protein (IGFBP)-1 in mice leads to vascular insulin sensitization, increased nitric oxide bioavailability, reduced atherosclerosis, and enhanced vascular repair, and in the setting of obesity improves glucose tolerance. Human studies suggest that low levels of IGFBP-1 are permissive for the development of diabetes and cardiovascular disease. Here we seek to determine whether loss of IGFBP-1 plays a causal role in the predisposition to cardiometabolic disease. Metabolic phenotyping was performed in transgenic mice with homozygous knockout of IGFBP-1. This included glucose, insulin, and insulin-like growth factor I tolerance testing under normal diet and high-fat feeding conditions. Vascular phenotyping was then performed in the same mice using vasomotor aortic ring studies, flow cytometry, vascular wire injury, and angiogenesis assays. These were complemented with vascular phenotyping of IGFBP-1 overexpressing mice. Metabolic phenotype was similar in IGFBP-1 knockout and wild-type mice subjected to obesity. Deletion of IGFBP-1 inhibited endothelial regeneration following injury, suggesting that IGFBP-1 is required for effective vascular repair. Developmental angiogenesis was unaltered by deletion or overexpression of IGFBP-1. Recovery of perfusion following hind limb ischemia was unchanged in mice lacking or overexpressing IGFBP-1; however, overexpression of IGFBP-1 stimulated hindlimb perfusion and angiogenesis in insulin-resistant mice. These findings provide new insights into the role of IGFBP-1 in metabolic and vascular pathophysiology. Irrespective of whether loss of IGFBP-1 plays a causal role in the development of cardiometabolic disorders, increasing IGFBP-1 levels appears effective in promoting neovascularization in response to ischemia.
No takes yet. Share an insight, caveat, or question.
Haywood et al. (2019) studied Cardiometabolic pathophysiology, insulin resistance, vascular injury, and hindlimb ischemia. IGFBP-1 deletion (loss-of-function) and human IGFBP-1 overexpression (gain-of-function) vs. Wild-type littermate control mice (and unstimulated/PBS control for in vitro HUVECs) was evaluated on Endothelial regeneration 5 days after femoral artery wire injury (% area regenerated) (p=≤0.05). IGFBP-1 deletion impaired endothelial regeneration after wire injury without altering glucose metabolism, while IGFBP-1 overexpression improved ischemic perfusion in insulin-resistant mice.
Synapse has enriched 10 related papers. Consider them for comparative context: